Skip to main content
BIOTRON LIMITED logo

BIOTRON LIMITED — Investor Relations & Filings

Ticker · BIT ISIN · AU000000BIT4 ASX Professional, scientific and technical activities
Open in API
Filings indexed 765 across all filing types
Latest filing 2019-12-10 Capital/Financing Update
Country AU Australia
Listing ASX BIT

About BIOTRON LIMITED

https://www.biotron.com.au

Biotron Limited is a clinical-stage company focused on the development of novel small molecule antiviral therapeutics. The company utilizes its proprietary ViroPore technology platform to design and develop drugs that target viroporins—a class of proteins found in a wide range of viruses that play critical roles in viral replication and the evasion of host immune responses. Biotron's primary clinical program centers on BIT225, a first-in-class inhibitor targeting the HIV-1 Vpu protein and the Hepatitis C virus p7 protein. The company aims to address unmet medical needs by developing treatments that can potentially eradicate viral reservoirs and improve patient outcomes. In addition to HIV and HCV, Biotron is exploring the application of its antiviral platform against other significant viral pathogens, including SARS-CoV-2, leveraging its expertise in ion channel-targeting chemistry to disrupt the viral life cycle.

Recent filings

Filing Released Lang Actions
Appendix 2A 15 pages 174.8KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes detailed information about the entity, the securities to be quoted, and the nature of the issue (options exercised or convertible securities converted). The document is a regulatory announcement related to capital markets activity, specifically the listing or quotation of securities. It is not a financial report, earnings release, or management discussion. It is also not a report publication announcement but a formal application for quotation of securities under ASX Listing Rules. This type of document fits best under the category of Capital/Financing Update (CAP), as it relates to changes in the company's capital structure and securities quotation.
2019-12-10 English
Change of Director's Interest Notice 3 pages 178.5KB
Director's Dealing Classification · 100% confidence The document is an Appendix 3Y, which is a Change of Director's Interest Notice filed under ASX Listing Rule 3.19A. It details the change in shareholdings of a company director, including the number of securities held before and after the change, the nature of the change (exercise of options), and other related information. This type of document is a report of personal share transactions by company directors and executives, which fits the definition of Director's Dealing (DIRS). The document is short (4287 characters) and does not contain financial statements or broader company financial information, so it is not an Annual Report or similar. Therefore, the correct classification is DIRS with high confidence.
2019-12-09 English
Appendix 2A 15 pages 497.8KB
Regulatory Filings Classification · 95% confidence The document is an Appendix 2A form submitted to the ASX (Australian Securities Exchange) for the application for quotation of securities. It includes details about the exercise of options and the resulting securities to be quoted. The document references Listing Rule 3.10.3B and contains detailed information about the securities being issued and quoted, including dates, numbers, and types of securities. This type of document is a regulatory announcement related to capital markets activities, specifically the application for quotation of securities following option exercises. It is not a financial report, earnings release, or management discussion, but rather a formal regulatory filing to the exchange about securities quotation. Therefore, it fits best under the category of Regulatory Filings (RNS).
2019-12-04 English
Change of Director's Interest Notice 3 pages 649.5KB
Director's Dealing Classification · 100% confidence The document is an Appendix 3Y form, which is a Change of Director's Interest Notice filed under ASX Listing Rule 3.19A. It details the acquisition and disposal of securities by a company director, Michelle Miller, including the exercise of options and changes in shareholdings. The document is a regulatory disclosure about insider trading by a director, not a financial report, earnings release, or management discussion. It fits the definition of Director's Dealing filings, which report personal share transactions by company directors and executives. The document length is about 4700 characters, consistent with a short regulatory notice rather than a full report. Therefore, the correct classification is DIRS (Director's Dealing).
2019-12-04 English
Presentation of HIV Data to CROI and New Patents 2 pages 104.5KB
Regulatory Filings Classification · 95% confidence The document is a short announcement (3125 characters) from Biotron Limited dated December 3, 2019, addressed to the ASX Limited. It informs about the company's upcoming presentation of clinical trial data at an international HIV/AIDS conference (CROI) and new patent applications filed. The content focuses on clinical trial updates, intellectual property, and future plans for clinical development. There are no financial statements, detailed financial data, or regulatory certifications included. The document is an announcement of upcoming events and developments rather than a full report or detailed financial disclosure. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing or certification. Given its nature as a corporate update about clinical data presentation and patent filings, it best fits the category of a Regulatory Filing (RNS), which serves as a general announcement category for miscellaneous filings that do not fit other specific categories.
2019-12-02 English
Appendix 3B 13 pages 995.8KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a New Issue Announcement and Application for Quotation of Additional Securities filed with the ASX (Australian Securities Exchange). It details the issuance of new fully paid ordinary shares, the number of securities issued, issue price, and compliance with ASX Listing Rules. The document includes sections on quotation agreements and calculation of placement capacity under ASX rules. It is not a financial report, earnings release, or management discussion, but a regulatory announcement about new share issuance and quotation application. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed information about the new issue, not just a brief announcement or a link to a report, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2019-11-27 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.